Once Weekly Bortezomib Decreases Rates of Peripheral Neuropathy Without Diminishing Efficacy As Compared to Twice Weekly Bortezomib in Combination with Lenalidomide, Dexamethasone and Daratumumab, a Single Center Retrospective Analysis